Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q3 2021 call → NOWe need to determine if the transcript conveys a situation where demand is already in hand, the constraint is on the receiving side (counterparties' ability to absorb), and they are working on clearing it, with business ahead. Let's analyze the transcript. The company is LeMaitre Vascular, selling medical devices. Key topics: sales growth, Delta variant impact, hiring sales reps, Artegraft acquisition, etc. The question asks about a specific scenario: management conveys that they already have business or demand secured, but the thing standing between them and meaningfully larger delivered business is the counterparties' own ability to receive, install, qualify, stock, staff, certify, onboard, or absorb it. And management describes those counterparties as already working on that preparation, with business mostly ahead. Look for any such description. The transcript discusses sales reps hiring, but that's the company's own sales force, not counterparties' receiving capacity. The Delta variant caused hospitals to defer elective surgery - that's a demand issue, not a receiving-side constraint being cleared. The company mentions back orders due to CE Mark issues, but that's regulatory, not counterparty absorption. There is mention of XenoSure CE Mark resolved, and back orders cleared. But that's about the company's own regulatory approval, not counterparties' readiness. The company talks about hiring sales reps to expand territories, but that's the company's own capacity to sell, not the buyers' ability to receive. The question specifically asks about a situation where the demand is already in hand, but the constraint is on the receiving side. For example, a buyer whose own sites must be stood up, or a partner whose onboarding must finish. There is no such description here. The transcript mentions "hospitals deferred elective surgery" - that's a demand deferral, not a receiving-side constraint being cleared. The company doesn't say hospitals are working on clearing that constraint. Also, the company talks about "back orders" but those are due to CE Mark issues, which are the company's own regulatory approvals, not counterparty readiness. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.